Evidence map›Paper›PMID 37836551›Full record

ReviewNutrients2023

Alpha-Glucosidase Inhibitory Peptides: Sources, Preparations, Identifications, and Action Mechanisms.

Han Lu, Tiantian Xie, Qi Wu, Zuomin Hu, Yi Luo, Feijun Luo

Open access · goldAbstract readReview
In one paragraph

Review in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Biochemistry and biophysics reports · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Han LuHunan Key Laboratory of Grain-Oil Deep Process and Quality Control, Central South University of Forestry and Technology, Changsha 410004, China.
Tiantian XieHunan Key Laboratory of Grain-Oil Deep Process and Quality Control, Central South University of Forestry and Technology, Changsha 410004, China.
Qi WuHunan Key Laboratory of Grain-Oil Deep Process and Quality Control, Central South University of Forestry and Technology, Changsha 410004, China.
Zuomin HuHunan Key Laboratory of Grain-Oil Deep Process and Quality Control, Central South University of Forestry and Technology, Changsha 410004, China.
Yi LuoDepartment of Gastroenterology, Xiangya School of Medicine, Central South University, Changsha 410008, China.
Feijun LuoHunan Key Laboratory of Grain-Oil Deep Process and Quality Control, Central South University of Forestry and Technology, Changsha 410004, China.
Central South University · CNCentral South University of Forestry and Technology · CN

Funding

the Key Project of State Key R & D Program, China No.2022YFF1100200the Natural Science Foundation of Hunan Province, China No.2021JJ31075the Program for Science & Technology Innovation Platform of Hunan Province 2019TP1029
6 · The paper itself

Abstract

With the change in people's lifestyle, diabetes has emerged as a chronic disease that poses a serious threat to human health, alongside tumor, cardiovascular, and cerebrovascular diseases. α-glucosidase inhibitors, which are oral drugs, have proven effective in preventing and managing this disease. Studies have suggested that bioactive peptides could serve as a potential source of α-glucosidase inhibitors. These peptides possess certain hypoglycemic activity and can effectively regulate postprandial blood glucose levels by inhibiting α-glucosidase activity, thus intervening and regulating diabetes. This paper provides a systematic summary of the sources, isolation, purification, bioavailability, and possible mechanisms of α-glucosidase inhibitory peptides. The sources of the α-glucosidase inhibitory peptides were introduced with emphasis on animals, plants, and microorganisms. This paper also points out the problems in the research process of α-glucosidase inhibitory peptide, with a view to providing certain theoretical support for the further study of this peptide.

Indexed as

Diabetes MellitusGlycoside Hydrolase Inhibitorsalpha-GlucosidasesAnimalsHumansHypoglycemic AgentsPeptidesalpha-GlucosidasesGlycoside Hydrolase InhibitorsHypoglycemic AgentsPeptidesbioavailabilitymechanismsourceα-glucosidase inhibitory peptide

Identifiers

PMID37836551
PMCPMC10574726
OpenAlexW4387404371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.